Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) welcome good news! Research shows that GLP-1 drugs can reduce the risk of cancer.

According to the latest findings published in the Journal of the American Medical Association Oncology, GLP-1 receptor agonists, such as Novo Nordisk's Ozempic and Eli Lilly's weight-loss and diabetes therapy Mounjaro, can reduce the risk of cancer.